Search

Your search keyword '"Leonard Appleman"' showing total 21 results
Start Over Author "Leonard Appleman"
21 results on '"Leonard Appleman"'

1. 351 KEYNOTE-365 cohort D: pembrolizumab plus abiraterone acetate and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)

Author

Urban Emmenegger, Christian Poehlein, Charles Schloss, Leonard Appleman, Loïc Mourey, Anthony Joshua, Mark Linch, Josep Piulats, Evan Yu, Johann De Bono, William Berry, Peter Fong, Cristiano Ferrario, Tilman Todenhoefer, Henry Conter, Brigitte Laguerre, Xin Tong Li, Michael Stoeckle, Jose Arranz, and Nataliya Mar

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2021
Full Text
View/download PDF

2. 347 KEYNOTE-365 cohort C: pembrolizumab + enzalutamide in patients with abiraterone acetate–pretreated metastatic castration-resistant prostate cancer (mCRPC)—data after minimum of 22 months of follow-up

Author

Urban Emmenegger, Howard Gurney, Emanuela Romano, Neal Shore, Margitta Retz, Christian Poehlein, Charles Schloss, Leonard Appleman, Gwenaelle Gravis, Loïc Mourey, Josep Piulats, Evan Yu, Johann De Bono, William Berry, Peter Fong, Cristiano Ferrario, Tilman Todenhoefer, Henry Conter, Brigitte Laguerre, and Xin Tong Li

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2021
Full Text
View/download PDF

3. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)

Author

Holden T Maecker, Lawrence Fong, Leonard D’Amico, Martin Cheever, Leonard Appleman, Steven P Fling, Nirasha Ramchurren, Russell Szmulewitz, Omer Kucuk, Paul Monk, Caroline Duault, Russell K Pachynski, Lauren Harshman, Rhonda L Bitting, Frederick Millard, John D Seigne, Bruce Hess, Andreanne Lacroix, Judith C Kaiser, Michel Morre, Anne Grégoire, and Evan Y Yu

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2021
Full Text
View/download PDF

4. Overall survival based on oncologist density in the United States: A retrospective cohort study.

Author

Sudeep K Siddappa Malleshappa, Smith Giri, Smit Patel, Tapan Mehta, Leonard Appleman, Scott F Huntington, Vida Passero, Rahul A Parikh, and Kathan D Mehta

Subjects
Medicine, Science
Abstract

Medically underserved areas (MUA) or health professional shortage areas (HPSA) designations are based on primary care health services availability. These designations are used in recruiting international medical graduates (IMGs) trained in primary care or subspecialty (e.g., oncology) to areas of need. Whether the MUA/HPSA designation correlates with Oncologist Density (OD) and supports IMG oncologists' recruitment to areas of need is unknown. We evaluated the concordance of OD with the designation of MUAs/HPSAs and evaluated the impact of OD and MUA/HPSA status on overall survival. We conducted a retrospective cohort study of patients diagnosed with hematological malignancies or metastatic solid tumors in 2011 from the Surveillance Epidemiology and End Results (SEER) database. SEER was linked to the American Medical Association Masterfile to calculate OD, defined as the number of oncologists per 100,000 population at the county level. We calculated the proportion of counties with MUA or HPSA designation for each OD category. Overall survival was estimated using the Kaplan-Meier method and compared between the OD category using a log-rank test. We identified 68,699 adult patients with hematologic malignancies or metastatic solid cancers in 609 counties. The proportion of MUA/HPSA designation was similar across counties categorized by OD (93.2%, 95.4%, 90.3%, and 91.7% in counties with 8.4 oncologists per 100K population, p = 0.7). Patients' median survival in counties with the lowest OD was significantly lower compared to counties with the highest OD (8 vs. 11 months, p

Published
2021
Full Text
View/download PDF

6. Annual Hospital Volume of High Dose Interleukin-2 and Inpatient Mortality in Melanoma and Renal Cell Carcinoma Patients.

Author

Kathan Mehta, Leonard Appleman, Hong Wang, Ahmad A Tarhini, and Rahul A Parikh

Subjects
Medicine, Science
Abstract

BACKGROUND:Immunotherapy using high dose interleukin-2 (HD IL2) in patients with renal cell carcinoma (RCC) and melanoma is associated with severe toxicities. The association between annual hospital volume of HD IL2 and inpatient mortality is not well studied. In this study we aim to quantify the impact of annual hospital volume of HD IL2 on inpatient mortality using National Inpatient Sample (NIS) data. METHODS:We did a cross-sectional study using NIS, one of the largest inpatient datasets in United States, from 2003 to 2011. Patients with melanoma and RCC receiving HD IL2 were identified by ICD9 procedure code 00.15. The primary outcome was inpatient mortality. Using Joinpoint regression, which detects change in trend of inpatient mortality with change in annual volume, the hospitals were classified in three volume categories (low: 1-40, medium: 41-120, high: >120). Multivariate logistic regression was used to identify predictors of inpatient mortality controlling for confounders. RESULTS:From 2003 to 2011, 29,532 patients with RCC or melanoma who received HD IL2 were identified, and 124 died during the hospitalization (0.4%). The hospitals with low, medium and high annual volume had significant difference in inpatient mortality (0.83%, 0.29% and 0.13% respectively, p = 0.0003). On multivariate analysis, low volume hospitals were associated with significantly higher odds of inpatient mortality (OR 6.1, 95% CI 1.6-23.2, p = 0.003) as compared to high volume hospitals. Additionally, the hospitals with annual volume of 1-20 had even higher rates (1.31% vs. 0.13%, p

Published
2016
Full Text
View/download PDF

7. LBA02-11 UPDATED PROGRESSION-FREE SURVIVAL FROM PRESTO: A PHASE 3 RANDOMIZED STUDY OF ANDROGEN ANNIHILATION FOR HIGH-RISK BIOCHEMICALLY RELAPSED PROSTATE CANCER (AFT-19)

Author

Rahul Aggarwal, Scott Eggener, Glenn Heller, Habn Xiao, David Hillman, Joel Picus, Jennifer Wang, Mary Ellen Taplin, Tanya Dorff, Leonard Appleman, Doug Weckstein, Akash Patnaik, Alan Bryce, Dan Shevrin, Susan Halabi, James Mohler, Daniel Anderson, Arpit Rao, Scott Tagawa, Alan Tan, Charles Ryan, and Michael Morris

Subjects
Urology
Published
2023
Full Text
View/download PDF

8. Supplementary Table S2 from Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Author

Mario Sznol, Jason S. Simon, John F. Kurland, Maria Jure-Kunkel, Shivani Srivastava, Petra Ross-Macdonald, Scott D. Chasalow, Tina C. Young, Lewis Cohen, Laurence Albiges, Lawrence Fong, Leonard Appleman, Elizabeth R. Plimack, Michael R. Harrison, Brendan Curti, Douglas G. McNeel, Jose Luis Perez-Gracia, Walter M. Stadler, Harriet Kluger, Charles G. Drake, David F. McDermott, Bernard Escudier, Mayer N. Fishman, and Toni K. Choueiri

Abstract

59 probesets from an analysis of blood These are probesets for which the null hypothesis was rejected and the change over time averaged over treatment groups was {greater than or equal to}1.2-fold.

Published
2023
Full Text
View/download PDF

9. Supplementary Figure S1 from Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Author

Mario Sznol, Jason S. Simon, John F. Kurland, Maria Jure-Kunkel, Shivani Srivastava, Petra Ross-Macdonald, Scott D. Chasalow, Tina C. Young, Lewis Cohen, Laurence Albiges, Lawrence Fong, Leonard Appleman, Elizabeth R. Plimack, Michael R. Harrison, Brendan Curti, Douglas G. McNeel, Jose Luis Perez-Gracia, Walter M. Stadler, Harriet Kluger, Charles G. Drake, David F. McDermott, Bernard Escudier, Mayer N. Fishman, and Toni K. Choueiri

Abstract

CONSORT diagram.

Published
2023
Full Text
View/download PDF

10. Supplementary Information from Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Author

Mario Sznol, Jason S. Simon, John F. Kurland, Maria Jure-Kunkel, Shivani Srivastava, Petra Ross-Macdonald, Scott D. Chasalow, Tina C. Young, Lewis Cohen, Laurence Albiges, Lawrence Fong, Leonard Appleman, Elizabeth R. Plimack, Michael R. Harrison, Brendan Curti, Douglas G. McNeel, Jose Luis Perez-Gracia, Walter M. Stadler, Harriet Kluger, Charles G. Drake, David F. McDermott, Bernard Escudier, Mayer N. Fishman, and Toni K. Choueiri

Abstract

Supplementary Information

Published
2023
Full Text
View/download PDF

11. Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score

Author

Matthew D. Galsky, Dean F. Bajorin, Johannes Alfred Witjes, Jürgen E. Gschwend, Yoshihiko Tomita, Federico Nasroulah, Jun Li, Sandra Collette, Begoña P. Valderrama, Marc-Oliver Grimm, Leonard Appleman, Gwenaelle Gravis, Andrea Necchi, Dingwei Ye, Frank Stenner, Megan Wind-Rotolo, Joshua Zhang, and Keziban Ünsal-Kaçmaz

Subjects
All institutes and research themes of the Radboud University Medical Center, Urology, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]
Abstract

Contains fulltext : 293187.pdf (Publisher’s version ) (Open Access)

Published
2023

12. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Penile Squamous Cell Carcinoma: An International Study from the Global Society of Rare Genitourinary Tumors

Author

Talal El Zarif, Amin Nassar, Gregory R. Pond, Tony Zibo Zhuang, Viraj A. Master, Bassel Nazha, Scot Niglio, Nicholas Simon, Andrew W. Hahn, Curtis A. Pettaway, Shi-Ming Tu, Noha Abdel-Wahab, Maud Velev, Ronan Flippot, Sebastiano Buti, Marco Maruzzo, Arjun Mittra, Jinesh Gheeya, Yuanquan Yang, Pablo Alvarez Rodriguez, Daniel Castellano, Guillermo de Velasco, Giandomenico Roviello, Lorenzo Antonuzzo, Rana R. McKay, Bruno Vincenzi, Alessio Cortellini, Gavin Hui, Alexandra Drakaki, Michael Glover, Ali Raza Khaki, Edward El-Am, Nabil Adra, Tarek H. Mouhieddine, Vaibhav Patel, Aida Piedra Cascon, Angela Gernone, Nancy B. Davis, Harrison Matthews, Michael R. Harrison, Ravindran Kanesvaran, Giulia Claire Giudice, Pedro Barata, Alberto Farolfi, Jae Lyun Lee, Matthew I. Milowsky, Charlotte Stahlfeld, Leonard Appleman, Joseph Kim, Dory Freeman, Toni K. Choueiri, Philippe E. Spiess, Andrea Necchi, Andrea Apolo, and Guru P. Sonpavde

Published
2023
Full Text
View/download PDF

13. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Author

Arlene O Siefker-Radtke, Andrea Necchi, Se Hoon Park, Jesús García-Donas, Robert A Huddart, Earle F Burgess, Mark T Fleming, Arash Rezazadeh Kalebasty, Begoña Mellado, Sergei Varlamov, Monika Joshi, Ignacio Duran, Scott T Tagawa, Yousef Zakharia, Sydney Akapame, Ademi E Santiago-Walker, Manish Monga, Anne O'Hagan, Yohann Loriot, Scott Tagawa, Aude Flechon, Boris Alexeev, Sergey Varlamov, Robert Huddart, Earle Burgess, Arash Rezazadeh, Arlene Siefker-Radtke, Yann Vano, Donatello Gasparro, Alketa Hamzaj, Eugeniy Kopyltsov, Jesus Gracia Donas, Begona Mellado, Omi Parikh, Peter Schatteman, Stephane Culine, Nadine Houédé, Sylvie Zanetta, Gaetano Facchini, Giorgio Scagliotti, Giovanni Schinzari, Jae Lyun Lee, Mikhail Shkolnik, Mark Fleming, Monica Joshi, Peter O'Donnell, Herbert Stöger, Karel Decaestecker, Luc Dirix, Jean Pascal Machiels, Dephine Borchiellini, Remy Delva, Frederic Rolland, Boris Hadaschik, Margitta Retz, Eli Rosenbaum, Umberto Basso, Alessandra Mosca, Hyo Jin Lee, Dong Bok Shin, Cristina Cebotaru, Victor Moreno, Jose Luis Perez Gracia, Alvaro Pinto, Wen-Pin Su, Shian-Shiang Wang, John Hainsworth, Ian Schnadig, Sandhya Srinivas, Nicholas Vogelzang, Wolfgang Loidl, Johannes Meran, Marine Gross Goupil, Florence Joly, Florian Imkamp, Theodor Klotz, Susanne Krege, Matthias May, Wolfgang Schultze-Seemann, Arne Strauss, Uwe Zimmermann, Daniel Keizman, Avivit Peer, Avishai Sella, Rossana Berardi, Ugo De Giorgi, Cora Nanette Sternberg, Sun Young Rha, Iurie Bulat, Adel Izmailov, Vsevolod Matveev, Vladimir Vladimirov, Joan Carles, Albert Font, Maribel Saez, Isabel Syndikus, Kathryn Tarver, Leonard Appleman, John Burke, Nancy Dawson, Sharad Jain, UCL - (SLuc) Service d'oncologie médicale, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Centre du cancer, and UCL - (SLuc) Unité d'oncologie médicale

Subjects
Carcinoma, Transitional Cell, Middle Aged, ErbB Receptors, Central Serous Chorioretinopathy, Urinary Bladder Neoplasms, Oncology, Quinoxalines, Mutation, Humans, Pyrazoles, Neoplasm Metastasis, Aged, Follow-Up Studies
Abstract

Background Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, was shown to be clinically active and tolerable in patients with advanced urothelial carcinoma and prespecified FGFR alterations in the primary analysis of the BLC2001 study at median 11 months of follow-up. We aimed to assess the long-term efficacy and safety of the selected regimen of erdafitinib determined in the initial part of the study. Methods The open-label, non-comparator, phase 2, BLC2001 study was done at 126 medical centres in 14 countries across Asia, Europe, and North America. Eligible patients were aged 18 years or older with locally advanced and unresectable or metastatic urothelial carcinoma, at least one prespecified FGFR alteration, an Eastern Cooperative Oncology Group performance status of 0–2, and progressive disease after receiving at least one systemic chemotherapy or within 12 months of neoadjuvant or adjuvant chemotherapy or were ineligible for cisplatin. The selected regimen determined in the initial part of the study was continuous once daily 8 mg/day oral erdafitinib in 28-day cycles, with provision for pharmacodynamically guided uptitration to 9 mg/day (8 mg/day UpT). The primary endpoint was investigator-assessed confirmed objective response rate according to Response Evaluation Criteria In Solid Tumors version 1.1. Efficacy and safety were analysed in all treated patients who received at least one dose of erdafitinib. This is the final analysis of this study. This study is registered with ClinicalTrials.gov, NCT02365597. Findings Between May 25, 2015, and Aug 9, 2018, 2328 patients were screened, of whom 212 were enrolled and 101 were treated with the selected erdafitinib 8 mg/day UpT regimen. The data cutoff date for this analysis was Aug 9, 2019. Median efficacy follow-up was 24·0 months (IQR 22·7–26·6). The investigator-assessed objective response rate for patients treated with the selected erdafitinib regimen was 40 (40%; 95% CI 30–49) of 101 patients. The safety profile remained similar to that in the primary analysis, with no new safety signals reported with longer follow-up. Grade 3–4 treatment-emergent adverse events of any causality occurred in 72 (71%) of 101 patients. The most common grade 3–4 treatment-emergent adverse events of any cause were stomatitis (in 14 [14%] of 101 patients) and hyponatraemia (in 11 [11%]). There were no treatment-related deaths. Interpretation With longer follow-up, treatment with the selected regimen of erdafitinib showed consistent activity and a manageable safety profile in patients with locally advanced or metastatic urothelial carcinoma and prespecified FGFR alterations.

Published
2022

14. COMPELLING DATA FOR TOMORROW.

Author

Leonard Appleman, J.

Abstract

The article comments on papers about treatments of patients with genitourinary cancer that were presented at the 2008 annual meeting of the American Society of Clinical Oncology. The papers focus on novel investigational agents, genetic and environmental influences on cancer risk, risk of adverse effects with ADT in prostate cancer and clinical benefit of satraplatin in prostate cancer.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results